CML to expand US API manufacturing facility
CML president and CEO Brian Scanlan said CML supports both increasing demand for its commercial products as well as its healthy pipeline of API’s in later phases of
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The collaboration, which leverages Astex’s fragment-based drug discovery platform, will focus on discovering and developing drug candidates targeting an undisclosed epigenetic target in a blood cancer. Astex president